Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novel therapeutics developer Pharmos Corporation has received a gross milestone payment of $12.1 million from Bausch & Lomb for the commercial launch of Zylet, a combination treatment for inflammatory eye conditions.
Subscribe to our email newsletter
Zylet, which was approved for marketing by the FDA on December 15, is part of the loteprednol etabonate business that Pharmos sold to Bausch & Lomb in 2001.
Pharmos also noted that an additional milestone payment could be earned based on Bausch & Lomb sales of Zylet over the next two years. The maximum future payment is $10 million.
Zylet is a combination anti-inflammatory and antibiotic (0.5% loteprednol etabonate and 0.3% tobramycin) to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of infection exists.
Zylet is the third product containing loteprednol etabonate approved by the FDA. Lotemax and Alrex have been marketed since 1998 as a result of three previous new drug application (NDA) approvals. Zylet represents the final product resulting from Pharmos’ earlier collaboration with Bausch & Lomb.